Background-Hypertrophic cardiomyopathy (HCM), typically characterized by asymmetrical left ventricular hypertrophy, frequently is caused by mutations in sarcomeric proteins. We studied if changes in sarcomeric properties in HCM depend on the underlying protein mutation. Methods and Results-Comparisons were made between cardiac samples from patients carrying a MYBPC3 mutation (MYBPC3 mut ; nϭ17), mutation negative HCM patients without an identified sarcomere mutation (HCM mn ; nϭ11), and nonfailing donors (nϭ12). All patients had normal systolic function, but impaired diastolic function. Protein expression of myosin binding protein C (cMyBP-C) was significantly lower in MYBPC3 mut by 33Ϯ5%, and similar in HCM mn compared with donor. cMyBP-C phosphorylation in MYBPC3 mut was similar to donor, whereas it was significantly lower in HCM mn . Troponin I phosphorylation was lower in both patient groups compared with donor. Force measurements in single permeabilized cardiomyocytes demonstrated comparable sarcomeric dysfunction in both patient groups characterized by lower maximal force generating capacity in MYBPC3 mut and HCM mn, compared with donor (26.4Ϯ2.9, 28.0Ϯ3.7, and 37.2Ϯ2.3 kN/m
genetic defect to cardiac dysfunction is currently largely unknown. Recent studies have shown that even before hypertrophy is overt, carriers of a HCM-causing sarcomere mutation demonstrate signs of cardiac dysfunction. 6 -9 Echocardiographic strain analysis in preclinical HCM patients with mutations in genes encoding ␤-myosin heavy chain (MYH7), cardiac myosin binding protein C (MYBPC3), cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), and ␣-tropomyosin (TPM1) demonstrated a reduced early diastolic velocity. 6 Systolic strain and strain rates were not different from controls in preclinical HCM patients, while systolic function was diminished in HCM patients with manifest ventricular hypertrophy. 6 Cardiac magnetic resonance evaluation of carriers with a Dutch founder mutation in MYBPC3 or a mutation in TPM1 confirmed diastolic dysfunction at the preclinical stage, evident from slower diastolic circumferential strain rate in septal and lateral regions of the LV. 8 Tissue Doppler imaging in MYBPC3 mutation carriers without LV hypertrophy also revealed diastolic abnormalities as a first feature of preclinical HCM. 9 Furthermore, structural abnormalities consisting of crypts were discerned in a large percentage of these preclinical patients. 10 Fibrosis, a hallmark of overt HCM, was not visible in preclinical HCM, but serum level of the profibrotic C-terminal propeptide of type I collagen already was elevated. 11 These data indicate that sarcomeric mutations initiate early modifications in myocardial structure and function.
Recently we have provided evidence for sarcomeric dysfunction in manifest HCM patients with truncating MYBPC3 founder mutations (c.2373dupG and c.2864_2865delCT). 12 The sarcomeric dysfunction included a reduction in maximal force generating capacity and a higher myofilament Ca 2ϩ -sensitivity compared with nonfailing human myocardium, which may be the result of altered sarcomeric protein composition as we observed haploinsufficiency (ie, reduced cardiac myosin binding protein C [cMyBP-C] protein expression) in these patients. Haploinsufficiency was confirmed and extended to HCM caused by missense MYBPC3 mutations. 13 In the present study we investigated if the changes in sarcomeric function and protein composition are specific for the MYBPC3 mutations or are part of the more general clinical HCM phenotype.
To this end sarcomeric protein analysis was combined with force measurements in cardiac cells from patients with LV outflow tract obstruction harboring a MYBPC3 mutation, and in mutation negative HCM patients in whom no mutation was identified on screening of 9 genes that most frequently cause HCM. 14 To investigate if sarcomere responsiveness to increased cardiac stress (as occurs during exercise) is preserved in HCM patients, force was measured at 2 different sarcomere lengths (ie, Frank-Starling mechanism) and after treatment with protein kinase A (PKA; ie, ␤-adrenergic receptor stimulation).
Our study showed depressed maximal force, higher Ca 2ϩ -sensitivity, and perturbed length-dependent activation of sarcomeres in HCM patients with normal LV function and impaired diastolic function irrespective of the mutant protein.
The high myofilament Ca 2ϩ -sensitivity may in part underlie LV diastolic dysfunction, while the hypocontractile sarcomeres (lower maximal force and impaired length-dependent activation) may contribute to disease progression in HCM.
Methods
An extended version of the methods section is provided as an online supplement (see the online-only supplement).
Myocardial Samples
Cardiac tissue was obtained from the LV septum of 17 HCM patients with a MYBPC3 mutation (MYBPC3 mut group), and 11 mutation negative HCM patients after detailed sequencing of 9 HCMassociated genes (MYBPC3, MYH7, TNNT2, TNNI3, MYL2, MYL3 , ACTC, TPM1 and CSRP3; 14 HCM mn group) that underwent myectomy to relieve LV outflow obstruction (Morrow procedure). The MYBPC3 mut group comprised patients with truncating mutations c.2373dupG (nϭ9) and 2864-_2865delCT (nϭ4), and splice site mutations c.927 to 2AϾG (nϭ3) and c.1458 to 1GϾC (nϭ1). Echocardiographic and clinical data of the patients are given in the Table. Nonfailing LV cardiac tissue was obtained from donor hearts (nϭ12; 13 to 65 years of age, mean 42Ϯ5 years; 8/4 male/female). The study protocol was approved by the local ethics committees and written informed consent was obtained.
Protein Analysis and Isometric Force Measurements
Analysis of sarcomeric protein phosphorylation [15] [16] [17] [18] [19] [20] and force measurements on single cardiomyocytes 21 was performed as described previously.
Data Analysis
Data are presented as meansϮSEM. Cardiomyocyte force values were averaged per sample. The Shapiro-Wilk test was used to analyze if data from different groups followed a normal distribution. When data were distributed normally and showed equal variances, mean values for MYBPC3 mut , HCM mn , and donor samples were compared using a 1-way ANOVA followed by a Bonferroni post test. When data were not distributed normally or showed unequal variances, mean values for MYBPC3 mut , HCM mn and donor samples were compared using a nonparametric Kruskal-Wallis test, followed by a Dunn Multiple Comparison Test. The effect of Ca 2ϩ on force development was tested in 2-way repeated measures ANOVA using averaged data per heart. Effects of exogenous PKA treatment in single cardiomyocytes were tested with repeated measures 2-way ANOVA, or 2-way ANOVA followed by a Bonferroni post test. PϽ0.05 was considered significant.
Results

Clinical Characteristics
Hypertrophic obstructive cardiomyopathy was evident from higher septal thickness (21Ϯ1 mm in both patient groups; normal value Ͻ13 mm) 22 and high LV outflow tract pressure gradient (84Ϯ4 and 95Ϯ7 mm Hg; normal value Ͻ30 mm Hg) 23 in MYBPC3 mut and HCM mn patients, respectively (Table) . LV systolic function was graded as normal (grade 1) in all patients except 1, in whom mild (grade 2) LV systolic dysfunction was observed (MYBPC3 mut patient 11). In contrast to the normal systolic function, impaired relaxation was observed in all patients (30% stage 1, 60% stage 2, and 10% stage 3 diastolic dysfunction). Figure 1A shows MYBPC3 mut , HCM mn , and donor samples separated by 1D-gel electrophoresis stained with SYPRO and ProQ Diamond to determine cMyBP-C protein level (relative to ␣-actinin) and sarcomeric protein phosphorylation, respectively. A significantly lower cMyBP-C protein level was found in MYBPC3 mut hearts compared with donor myocardium (Figure 
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Sarcomere Dysfunction in Human HCM1B; PϽ0.0001 in 1-way ANOVA), which was not observed in HCM mn . Previous studies indicated ischemia-induced degradation of cMyBP-C at the N-terminus. 24, 25 To exclude that cMyBP-C degradation underlies the lower expression of fulllength cMyBP-C in MYBPC3 mut , Western blot analysis was performed with a specific antibody directed at the N-terminus of cMyBP-C. No degradation products were observed in any of the samples from the patients ( Figure 1C ) and donors. Furthermore, absence of smaller cMyBP-C products indicates absence of truncated forms of cMyBP-C (encoded by the mutated allele) in the sarcomeres. Phosphorylation of cMyBP-C normalized to its own expression level did not differ from donor in MYBPC3 mut , while it was significantly lower in HCM mn ( Figure 1D ; Pϭ0.001 in Kruskal-Wallis test). Figure 1E illustrates that, when normalized to ␣-actinin, the level of phosphorylated cMyBP-C is independent of cMyBP-C expression in the patient groups and significantly lower in both MYBPC3 mut and HCM mn compared with donor.
To further unravel the differences in cMyBP-C phosphorylation between MYBPC3 mut and HCM mn , we performed Western blot analysis with phospho-specific antibodies (Figure 2A) . The level of Ser273-phosphorylated cMyBP-C was significantly lower in HCM mn compared with donor, while an intermediate value was observed in MYBPC3 mut ( Figure 2B ; Pϭ0.04 in Kruskal-Wallis test). Ser282-phosphorylated cMyBP-C also was significantly lower in HCM mn , but unaltered in MYBPC3 mut compared with donor ( Figure 2B ; Pϭ0.04 in Kruskal-Wallis test). No significant difference was present in Ser302-phosphorylated cMyBP-C among groups ( Figure 2B ; Pϭ0.25 in 1-way ANOVA).
Phosphorylation of the other PKA target protein, cardiac troponin (cTnI), was significantly lower in both patient groups compared with donor ( Figure 3A ; PϽ0.0001 in Kruskal-Wallis test). The level of PKA (Ser22/23)-phosphorylated cTnI was significantly lower in both MYBPC3 mut and HCM mn compared with donor ( Figure 3B ; Pϭ0.0002 in Kruskal-Wallis test), while signals at the protein kinase C site Thr143 were extremely low in all groups (data not shown), indicating that the lower overall cTnI phosphorylation in patient samples compared with donor is mainly because of lower phosphorylation at PKA sites. cTnI also was separated on a Phos-tag polyacrylamide gel and subsequently stained on Western blots with a cTnI specific antibody ( Figure 3C ). This analysis yielded the distribution pattern of un-(0P), mono-(1P), and bis-(2P) phosphorylated cTnI. The distribution of the cTnI forms was significantly different among the 3 groups ( Figure 3D ; tested in 2-way ANOVA; interaction PϽ0.05). The relative levels of un-and monophosphorylated cTnI were higher in both HCM patient groups compared with donor, while the proportion of bisphosphorylated cTnI was lower, confirming the low overall cTnI phosphorylation observed in these patients with ProQ analysis ( Figure 3A ). ), but the difference was not significant (Pϭ0.68 in Kruskal-Wallis test). Figure 4C shows force-calcium relations for all groups at a sarcomere length of 2.2 m; force at submaximal [Ca 2ϩ ] was normalized to maximal force at saturating [Ca 2ϩ ]. The force-calcium relation in both patient groups was shifted to the left compared with donor, indicating a higher myofilament Ca 2ϩ -sensitivity. The relations between force and [Ca 2ϩ ] were significantly different among groups (interaction Diamond for analysis of cMyBP-C and cardiac troponin I protein phosphorylation. B, Protein level of cMyBP-C was significantly lower in MYBPC3 mut compared with HCM mn and donor samples. C, Western blot analysis of cMyBP-C did not reveal truncated or degradation products with a specific antibody. D, Phosphorylation of cMyBP-C (normalized to its own expression level) was significantly lower in HCM mn samples compared with MYBPC3 mut and donor tissue. E, Phosphorylated cMyBP-C (normalized to ␣-actinin), as an indirect measure of kinase activity, plotted against cMyBP-C expression (normalized to ␣-actinin) to illustrate that the degree of phosphorylation is independent of cMyBP-C protein expression in the HCM patient groups, and significantly lower compared with nonfailing donor myocardium. Figure 4D ; Pϭ0.04 in 1-way ANOVA). In addition, the steepness (nH) of the force-calcium relation was significantly lower in both patient groups (3.1Ϯ0.0.2 and 3.0Ϯ0.0.2 in MYBPC3 mut and HCM mn , respectively) compared with donor (3.7Ϯ0.1; Figure 4E ; Pϭ0.02 in Kruskal-Wallis test).
Sarcomeric Dysfunction in Manifest HCM Independent of MYBPC3 Mutation
Myofilament Length-Dependent Activation
To assess the length-dependent activation of myofilament contraction, force was measured at a sarcomere length of 1.8 and 2.2 m ( Figure 5A ) in 43 cells from 13 MYBPC3 mut hearts, 36 cells from 8 HCM mn hearts, and 32 cardiomyocytes from 9 donor hearts. These measurements were performed in subsets of patients with clinical characteristics similar to the group averages, because of tissue availability. In all groups, an increase in sarcomere length from 1.8 to 2.2 m increased maximal force, passive force, and Ca ] value force, development by the sarcomeres will be somewhat higher in MYBPC3 mut and HCM mn compared with donor. 
Effects of Protein Kinase
lower phosphorylation was observed at Ser273 and Ser282 in HCM mn compared with donor, while no significant differences in phosphorylation at Ser273, Ser282, and Ser302 were found between MYBPC3 mut and donor hearts. *PϽ0.05 versus donor in Dunn Multiple Comparison Test or Bonferroni post test.
ence in Ca 2ϩ
-sensitivity of force between patient groups and donor as shown in Figure 6A . Figure 6B illustrates that after PKA, force development was depressed in patient cells compared with donor both at maximal and submaximal [Ca 2ϩ ] (interaction Pϭ0.005 in 2-way repeated measures ANOVA).
Interestingly, PKA pretreatment of cells significantly enhanced the sarcomere length-dependent change in Ca 2ϩ -sensitivity (⌬EC 50 ) in MYBPC3 mut (4 hearts, 14 cells) and HCM mn (4 hearts, 15 cells), but not in donor (4 hearts, 12 cells; Figure 7 ; Pϭ0.009 in 2-way ANOVA). The blunted shift in EC 50 on an increase in sarcomere length from 1.8 to 2.2 m in patient groups compared with donor cells at baseline was absent on PKA pretreatment (Figure 7) .
Discussion
This study is the first to compare both protein composition and function of the sarcomeres in well-defined HCM patient groups with MYBPC3 mutations and without an identified sarcomere mutation. The observed differences in sarcomere function seem to reflect the clinical HCM phenotype rather than the specific MYBPC3 mutation. Despite normal LV systolic function, the force generating capacity of the sarcomeres was lower and sarcomere responsiveness to an increase in sarcomere length was blunted (ie, reduced length dependent activation). The perturbations in sarcomere function may contribute to HCM disease progression.
Cardiac MyBP-C Haploinsufficiency is Unique for HCM With MYBPC3 Mutations
Our study revealed that cMyBP-C haploinsufficency is not a general feature of HCM. As cMyBP-C exerts a role in myofilament assembly and integrity, 24 the lower expression of cMyBP-C may underlie disease pathogenesis by disruption of myocardial structure. HCM patients with a MYBPC3 mutation were younger (Pϭ0.05) than HCM mutation negative individuals, which suggests that the sarcomere mutation itself is a detrimental modifier of disease progression. In accordance, Olivotto et al 26 reported an increased risk to develop severe LV dysfunction and progress to end-stage heart failure in patients with an identified sarcomere mutation (both thin and thick filament mutations) compared with mutation negative patients. Cardiac remodeling, including cardiac myocyte disarray and fibrosis, has been observed in homozygous cMyBP-C knockout mice, in which cMyBP-C was completely absent. 27, 28 At 11 months of age heterozygous cMyBP-C null mice that only expressed Ϸ75% of normal cMyBP-C content showed asymmetrical septal hypertrophy and signs of fibrosis, while no morphological changes were observed at 3 to 4 months of age. 28 Future longitudinal studies should be performed to answer the question if cMyBP-C haploinsufficiency exerts a detrimental effect on the development of hypertrophic cardiomyopathy in patients with MYBPC3 mutations.
Reduced Phosphorylation of PKA Target Proteins
Lower phosphorylation of cTnI compared with donor hearts was evident in both HCM groups and may reflect a posttranslational phenotype-related protein modification. Low phosphorylation of cTnI compared with nonfailing donor hearts has been observed in previous studies in end-stage failing hearts from patients with idiopathic or ischemic dilated cardiomyopathy, 21,29 -31 and thus appears to be a general feature of progressive cardiac disease consistent with 
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down-regulation and desensitization of the ␤-adrenergic receptor pathway. 32 Western blot analysis confirmed lower phosphorylation at the PKA sites of cTnI in both MYBPC3 mut and HCM mn samples compared with donor ( Figure 3B) . Phosphorylation of the other PKA target protein cMyBP-C also was lower in the HCM mn group, but was relatively high in MYBPC3 mut samples ( Figure 1D ). cMyBP-C has 3 putative phosphorylation sites (Ser273, Ser282, and Ser302) that are substrates for PKA, protein kinase C, and calcium-calmodulindependent kinase. 33, 34 Analysis of site-specific cMyBP-C phosphorylation using phospho-specific antibodies against these sites (Figure 2) confirmed the "high" phosphorylation of cMyBP-C in MYBPC3 mut , as phosphorylation at all sites did not significantly differ from the donor group. A significantly lower phosphorylation at Ser273 and Ser282 was observed in the HCM mn samples compared with donor hearts. Similarly, a recent study by Copeland et al 17 reported a reduction in total cMyBP-C phosphorylation in HCM myectomy samples to 39% of the value found in nonfailing myocardium. Our analysis did not reveal a significant difference in phosphorylated Ser302 between MYBPC3 mut , HCM mn , and donor samples ( Figure 2B ). Recent studies indicated that Ser302 is phosphorylated by calciumcalmodulin-dependent kinase, which is activated on an increase in heart rate, rather than by PKA. 35, 36 Hence, the significantly lower total cMyBP-C phosphorylation observed in HCM mn compared with donor may be the result of reduced PKAmediated phosphorylation compared with nonfailing donor myocardium. The divergent phosphorylation pattern of the PKA targets, cTnI, and cMyBP-C in the MYBPC3 mut samples may be well-explained by an altered stoichiometry between protein level and PKA expression or its activity. This is illustrated in Figure  1E , which shows that the level of phosphorylated cMyBP-C, which reflects kinase activity, is independent of cMyBP-C expression in the patient groups and significantly lower in both MYBPC3 mut and HCM mn compared with donor.
Lower Force Generating Capacity and Higher Ca
2؉ -Sensitivity: Common Sarcomere Features of HCM
Our data suggest that low maximal force generating capacity of sarcomeres is a general feature of HCM patients, while passive force is higher only in a few HCM samples with a MYBPC3 mutation (Figure 4) . A recent study by Hoskins et al 37 demonstrated a 40% lower maximal isometric force in 6 HCM hearts with mutations in MYBPC3, MYH7, or no identified mutation, while passive stiffness of the cardiomyocytes was not different ] at which 50% of maximal force is reached (ie, EC 50 ) was significantly lower in patient groups compared with donor. D shows EC 50 values for individual heart samples. In addition, steepness of the force-calcium relations (nH) was significantly lower in patient groups compared with donor (C and E). from donor. Thus, the significantly lower maximal force generating capacity appears to be characteristic for the clinical HCM phenotype. Other intrinsic alterations within the sarcomeres, which have been described in diseased myocardium (eg, sarcomeric disarray, oxidative modifications) or a reduction of myofibrillar density may explain the lower maximal isometric force. Interestingly, HCM is regarded as a disease with hyperdynamic LV function, which may evolve to end-stage failure with systolic dysfunction. 26 Our patient group showed normal systolic LV function. Therefore, the hypocontractile sarcomeres may not have a large impact on systolic performance, but may contribute to disease progression of HCM.
In vivo studies in preclinical HCM patients reported diastolic dysfunction as one of the earliest signs of cardiac dysfunction. 6 -9 In our previous studies in patients with diastolic heart failure (ie, heart failure with preserved ejection fraction), we found that passive stiffness is an important determinant of the high LV end-diastolic pressures observed in diastolic heart failure. 38 In the present study, we did not find a significantly higher passive stiffness in both HCM patient groups, although Fpas was higher in several of the MYBPC3 mut samples compared with nonfailing donor ( Figure 4B) . A reduction in myofibrillar density, which may be part of HCM myocardial remodelling, would mask stiffening of sarcomeres. In order to separate mutation-from remodelling-related changes in cardiomyocyte function, in our future studies we will investigate myofibrillar density and cardiomyocyte force characteristics in HCM in comparison with patients with aortic stenosis-induced hypertrophy. These future studies will reveal if stiffening of sarcomeres contributes to diastolic dysfunction in (preclinical) HCM patients, and may be a target for therapy in the early stage of HCM.
A higher Ca 2ϩ -sensitivity of myofilaments has been reported previously in end-stage dilated and ischemic human cardiomyopathy, 16, 30 and has been associated with lower PKA-mediated 
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phosphorylation of cTnI and cMyBP-C. 21, 29, 30 Both cMyBP-C and cTnI have a central role in regulating cardiac performance in response to ␤-adrenergic receptor stimulation as occurs during exercise. Apart from changes in calcium handling (via phosphorylation of L-type calcium channels, ryanodine receptors, and phospholamban), which increase systolic force development, 39 positive lusitropic effects (ie, increased relaxation) are in part mediated via a reduction in myofilament Ca 2ϩ -sensitivity and increased cross-bridge cycling kinetics. PKA-induced myofilament desensitization is mediated via phosphorylation of both cTnI and cMyBP-C. 40 -42 PKA treatment abolished the initial differences in EC 50 among groups ( Figure 6A ), indicating that the higher Ca 2ϩ -sensitivity is because of lower phosphorylation of cMyBP-C and cTnI. Apart from phosphorylation deficits, the lower cMyBP-C expression in the MYBPC3 mut group may alter myofilament Ca 2ϩ -sensitivity. A higher myofilament Ca 2ϩ -sensitivity has been reported in cardiomyocytes on extraction of cMyBP-C and in cMyBP-C knock-out mice. 40, 43 This indicates that apart from reduced PKA-mediated sarcomere phosphorylation, cMyBP-C haploinsufficiency in the MYBPC3 mut group may in part underlie the higher baseline Ca 2ϩ -sensitivity. The combination of a lower maximal force, higher Ca 2ϩ -sensitivity, and lower cooperativity of force development as shown in Figure 5B indicates that the sarcomere differences compared with nonfailing myocardium may lower systolic function at high intracellular [Ca 2ϩ ] and may somewhat limit myocardial relaxation at low [Ca 2ϩ ] in human HCM. Of note, during increased cardiac stress, ie, after treatment with exogenous PKA, HCM sarcomeres are hypocontractile at all calcium concentrations compared with nonfailing donor hearts ( Figure  6B ), suggesting that perturbed sarcomeric properties of manifest HCM may compromise systolic performance of the heart, in particular during increased cardiac load.
Blunted Length-Dependent Activation in HCM
In addition to the regulatory effect of the sarcomeres during increased sympathetic activity, the Frank-Starling mechanism, which provides a beat-to-beat regulating mechanism of systolic performance on enhanced ventricular filling (ie, increased enddiastolic volume), is caused by an increase in both maximal force generating capacity and Ca 2ϩ -sensitivity of the sarcomeres. 44, 45 Again, one of the possible mediating proteins involved in the increased force development on an increase in sarcomere length is cMyBP-C, as the length-dependent activation of force was significantly blunted in muscle strips from cMyBP-C deficient mice. 40 Interestingly, assessment of regional myocardial function with cardiac magnetic resonance imaging indicated blunting of the Frank-Starling mechanism in MYBPC3 mutation carriers compared with healthy individuals, 8 which may involve mutant MYBPC3. However, as similar changes in length-dependent activation of the sarcomeres were observed in patients with and without MYBPC3 mutations, the blunted length-dependent increase in myofilament Ca 2ϩ -sensitivity most likely is related to the secondary HCM disease phenotype. Konhilas et al 46 showed reduced length-dependent activation in myocytes from mouse myocardium harboring skeletal TnI, which lacks the PKA phosphorylation sites. Moreover, the length-dependent activation was enhanced on treatment with PKA in cardiomyocytes from nontransgenic mice. 46 Likewise, in the present study, incubation with PKA restored the lengthdependent increase in Ca 2ϩ -sensitivity in both HCM groups to the response observed in donor ( Figure 7) . As PKA incubation -sensitivity response and allow for an increase on increased sarcomere length.
Limitations and Clinical Implications
As all HCM patients received drug therapy, we cannot exclude effects of medication on the outcome of our study. Recently, we have shown that ␤-blocker therapy (bisoprolol) in pigs with a myocardial infarction corrected sarcomeric dysfunction in infarct animals to levels found in sham animals. 47 Moreover, maximal force development of single cardiomyocytes was significantly higher in heart failure patients who received chronic ␤-blocker treatment compared with patients who did not receive ␤-blockers. 48 Hence, the lower maximal force of HCM cardiomyocytes compared with donors may be somewhat underestimated because of positive effects of ␤-blocker treatment. As overall drug treatment was similar in the HCM patient groups we assume that any effect of medication will be equal in both groups.
In conclusion, investigation of protein composition and function of the sarcomeres in a large well-characterized HCM patient group with MYBPC3 mutations and without identified mutations revealed cMyBP-C haploinsufficiency to be unique for HCM patients with MYBPC3 mutations, while lower protein phosphorylation compared with nonfailing myocardium appears common for the clinical HCM phenotype. The hypocontractile sarcomeres seem to be characteristic of hypertrophic cardiomyopathy patients, as our previous studies in cardiomyocytes from patients with ischemic and idiopathic cardiomyopathy showed similar maximal force development as observed in nonfailing donor cells. 31 A lower PKA-mediated protein phosphorylation may in part underlie differences in sarcomere function between human HCM and nonfailing hearts, yielding a higher Ca 2ϩ -sensitivity and a blunted length-dependent sarcomere responsiveness, which may explain defects in activation and relaxation of the heart muscle in HCM patients with normal LV function and diastolic dysfunction.
